Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Open access
Haberman, Rebecca H, Herati, Ramin, Simon, David, Samanovic, Marie, Blank, Rebecca B, Tuen, Michael, Koralov, Sergei B, Atreya, Raja, Tascilar, Koray, Allen, Joseph R, Castillo, Rochelle, Cornelius, Amber R, Rackoff, Paula, Solomon, Gary, Adhikari, Samrachana, Azar, Natalie, Rosenthal, Pamela, Izmirly, Peter, Samuels, Jonathan, Golden, Brian, Reddy, Soumya M, Neurath, Markus F, Abramson, Steven B, Schett, Georg, Mulligan, Mark J, Scher, Jose U·2021·Annals of the Rheumatic Diseases

Abstract

ABSTRACT Objective To investigate the humoral and cellular immune response to mRNA COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment. Methods Established patients at NYU Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunization. Healthy subjects served as controls (n=26). IgG antibody responses to the spike protein were analyzed for humoral response. Cellular immune response to SARS-CoV-2 was further analyzed using high-parameter spectral flow cytometry. A second independent, validation cohort of controls (n=182) and patients with IMID (n=31) from Erlangen, Germany were also analyzed for humoral immune response. Results Although healthy subjects (n=208) and IMID patients on biologic treatments (mostly on TNF blockers, n=37) demonstrate robust antibody responses (over 90%), those patients with IMID on background methotrexate (n=45) achieve an adequate response in only 62.2% of cases. Similarly, IMID patients do not demonstrate an increase in CD8+ T cell activation after vaccination. Conclusions In two independent cohorts of IMID patients, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunization efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines. KEY MESSAGES What is already known about this subject? The impact of COVID-19 has been felt across the globe and new hope has arisen with the approval of mRNA vaccines against the SARS-CoV-2. Studies have shown immunogenicity and efficacy rates of over 90% in the immunocompetent adult population. However, there is a lack of knowledge surrounding the response of patients with immune-mediated inflammatory diseases (IMIDs) who may also be on immunomodulatory medications. Patients with IMID have been shown to have attenuated immune responses to seasonal influenza vaccination. What does this study add? This study looks at the humoral and cellular immune response to two doses of BNT162b2 mRNA COVID-19 Vaccine in participants with IMID (on immunomodulators) compared with healthy controls. Individuals with IMID on methotrexate demonstrate up to a 62% reduced rate of adequate immunogenicity to the BNT162b2 mRNA vaccination. Those on anti-cytokine or non-methotrexate oral medications demonstrate similar levels of immunogenicity as healthy controls (greater than 90%). Similarly, vaccination did not induce an activated CD8+ T cell response in participants on background methotrexate, unlike healthy controls and patients with IMID not receiving methotrexate. How might this impact of clinical practice or future developments? These results suggest that patients on methotrexate may need alternate vaccination strategies such as additional doses of vaccine, dose modification of methotrexate, or even a temporary discontinuation of this drug. Further studies will be required to explore the effect of these approaches on mRNA vaccine immunogenicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2021-220597

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 272

Metadata

Authors
Haberman, R. H., Herati, R., Simon, D., Samanovic, M., Blank, R. B., Tuen, M., Koralov, S. B., Atreya, R., Tascilar, K., Allen, J. R., Castillo, R., Cornelius, A. R., Rackoff, P., Solomon, G., Adhikari, S., Azar, N., Rosenthal, P., Izmirly, P., Samuels, J., Golden, B., Reddy, S. M., Neurath, M. F., Abramson, S. B., Schett, G., Mulligan, M. J., & Scher, J. U.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2021-10
Volume
80
Issue
10
Pages
1339-1344
ISSN
0003-4967 (ISSN-L)
OpenAlex
W3164513520
Cited by
272
References
22
FWCI
18.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. https://app.cochat.ai/papers/10.1136/annrheumdis-2021-220597
The paper
Haberman, R. H., Herati, R., Simon, D., Samanovic, M., Blank, R. B., Tuen, M., Koralov, S. B., Atreya, R., Tascilar, K., Allen, J. R., Castillo, R., Cornelius, A. R., Rackoff, P., Solomon, G., Adhikari, S., Azar, N., Rosenthal, P., Izmirly, P., Samuels, J., . . . Scher, J. U. (2021). Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-220597

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.